By Stephen Nakrosis

CoLabs Int’l Corp. plans to sell 1.3 million shares of common stock in an initial public offering, according to a filing on Monday.
The company expects the offering to price between $4 and $5 per share.

The pharmaceutical company said its technology places over-the-counter drugs, pharmaceuticals, and chemicals into “micro-sized, electrostatically charged encapsulates as well as into other types of micro-encapsulates.”
The company said in its filing with the SEC it applied to list on the Nasdaq Capital Market under the ticker symbol CLLB.
CoLabs Int’l said it had revenue of $157,000 for the year-ended December 31, compared with $80,000 for the prior year.
Craft Capital Management LLC and R.F. Lafferty & Co. Inc. are listed as the offering’s underwriters.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com